Filing Flows › Comparisons › OLN vs CC
Olin vs Chemours: OLN and CC compared
Olin is the larger company: $1.7B of revenue in its latest quarter (Q3 2026) against $1.5B for Chemours (Q3 2026). Chemours is growing faster (+3% against +2% a year earlier). Chemours is more profitable, with an operating margin of 14.4% against 3.4%.
Where the money goes: OLN and CC
Olin (OLN) · Q3 2026
Olin, Q3 2026: revenue $1.7B (+2% year over year), operating margin 3.4%, net earnings $14.4M, operating cash flow $110M. The chart follows the revenue to costs, profit and cash.
Chemours (CC) · Q3 2026
Chemours, Q3 2026: revenue $1.5B (+3% year over year), operating margin 14.4%, net earnings $196M, operating cash flow $149M. The chart follows the revenue to costs, profit and cash.
| Olin (OLN) | Chemours (CC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.7B | $1.5B |
| Revenue growth, Y/Y | +2% | +3% |
| Gross margin | 9.9% | 15.0% |
| Operating margin | 3.4% | 14.4% |
| Net earnings | $14.4M | $196M |
| Net margin | 0.8% | 12.7% |
| Operating cash flow | $110M | $149M |
| Free cash flow | $76.5M | $98.0M |
| Market value | $2.0B | $1.9B |
| Analysts’ mean target | $19.38 | $16.10 |
Where the revenue comes from
Olin
- Chlor Alkali Products and Vinyls: $851M (49%)
- Winchester: $485M (28%)
- Epoxy: $412M (24%)
Chemours
- All Segments: $1.5B (99%)
- Other Non-Reportable Segment: $13.0M (1%)
Questions
Which is bigger, Olin or Chemours?
Olin is the larger company: $1.7B of revenue in its latest quarter (Q3 2026) against $1.5B for Chemours (Q3 2026).
Is Olin or Chemours growing faster?
Chemours is growing faster (+3% against +2% a year earlier).
Which is more profitable, Olin or Chemours?
Chemours is more profitable, with an operating margin of 14.4% against 3.4%.
More: Olin earnings · how Olin makes money · Chemours earnings · how Chemours makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.